Announcements
W Hinterberger(Ludwig Boltzmann Institute for Cardiovascular Research), G. Cappellato, S. Dmochewitz, Emmanuel F. Ashong, G. Ruzza, Olimpia Pérez-Bández, Reuven Or(Hadassah Academic College), Sinasi Özsoylu, Carmen Amesty, Dominique Werner, K. Ballschmiter, Pedro P. Hernández(Centre National de la Recherche Scientifique), Elizabeth Naparstek(Hebrew University of Jerusalem), José María Guevara I., Δημήτρης Λουκόπουλος, Ernest Beutler(Scripps Health), Michael John Glyn Thomas, V. Anselstetter, H. Heimpel, Gilberto Garlín, O. Castillo, Xenophon Yataganas, Mazen Elias, Margareta Fischer, Shinya Fujii, A.M. Kambal, D. Cowan, Peter A. Lorkin, John Meletis(Athens State University), C. Cruz, S. Shilo, Gershom Zajicek, P. Fessas, Klaus Lechner, Klaus Geissler, Aaron Polliack(Hadassah Medical Center), Robert Marcus(King's College Hospital), A. H. Goldstone, Eliezer A. Rachmilewitz(Hebrew University of Jerusalem), E.S. Parry, M. Vicarioto, E. R. Huehns(University College Hospital), M.A. Babiker, C Hershko, Frode K. Rømer, George D. Eliopoulos(University of Crete), Eva Kabrna, A Girolami, Tulio Arends
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?
|Blood|2005|970
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859